I would like to begin by citing what is one of the earliest characteristics of the eye with primary open-angle glaucoma. This characteristic is not, as you may expect me to say, the simple increase of intraocular pressure, but an increase in fluctuation of the intraocular pressure. A definition of glaucoma in these terms is not new and I could not find words which express this viewpoint more clearly than those of Duke-Elder when he said in his Proctor Lecture (1952) that simple glaucoma was 'characterized initially by an instability of the ocular tension which shows a diurnal phasic variation of more than 5 mmHg, a state which usuallybut not invariablyresults in a permanent increase'.
This pressure fluctuation cannot adequately be explained as a result of the failure of the aqueous humour to drain from the eye due to an increased resistance, i.e. organic blockage in the trabecular meshwork. It can, however, be fully explained by the following concept concerning the nature of glaucoma. Glaucoma is a vascular disease which develops from a failure of adrenergic mechanisms to regulate pressure in the normal eye.
Glaucoma: Loss of Regulatory Capacity Keeping in mind the concept of glaucoma as a functional disease of neurovascular systems within the eye, let us look at intraocular pressure and the capacity of the body to regulate pressure more closely. The intraocular pressures of normal eyes of both animals and man are similar in magnitude and show extremely little variation from day to day (Table 1 ). This similarity between species exists in spite of marked anatomical differences in the tissues through which aqueous humour enters and leaves the eye. In order to determine the regulatory capacity, pressure must be disturbed and a measurement made of the mechanism in action. Manometric procedures have been developed and used for this purpose in both animals and man (Langham 1959 , Langham & Eisenlohr 1963 , Langham 1967 ) but these are not adaptable for studies on conscious subjects. It was therefore necessary to develop an alternative approach which would simulate the manometric technique and this was achieved in the pressure cup procedure (Langham 1962 (Langham , 1963 ). An accumulation of aqueous humour is effected by a temporary occlusion of the outflow vessels. An occlusion induced by the application of the pressure cup for ten minutes gives an average pressure increment of 8 mmHg which is sufficient in clinical studies to allow an accurate analysis of the rate of recovery of the intraocular pressure; in normal eyes this pressure increment corresponds to a total accumulation of 14,l of aqueous humour. Following release of the occlusion, the excess pressure decreases to its initial value, i.e. its normal value, as a simple exponential function of time. For a normal adult eye the excess pressure declines at approximately 12% per minute (i.e. the decay constant is O-12). It is the value of this decay constant which defines for an individual eye its regulatory capacity (Langham 1963 , Langham & Maumenee 1964 , Langham 1967 . Since initiating studies with this procedure in 1958 at the Institute of Ophthalmology in London we have made detailed analyses on more than 1,000 normal subjects, glaucoma patients and glaucoma suspects.
A dramatic change in the capacity of normal human eyes to regulate intraocular pressure was found to occur early in life and by the age of 40 to 60 years the mean value had decreased by more than 50 % (Fig 1) . It is of fundamental importance that this is not reflected in a corresponding increase in intraocular pressure.
In patients with open-angle glaucoma, the regulatory capacity is always severely impaired, and appears absent in approximately 50 % (Langham & Maumenee 1964 , Rosenthal 1969 . Thus the increased pressure resulting from the accumulation of aqueous humour during occlusion of the drainage channels either fails to fall to the initial pressure or decreases at a very slow rate towards it.
Medical treatment of glaucoma patients may improve the regulatory capacity but will not generally bring the capacity within a normal range of values (Langham 1967) . Similarly, the regulatory capacity has been found to be absent or seriously impaired in those glaucoma patients who subsequently developed ocular hypotension with onset of retinal detachment (Langham & Regan 1968 ).
On the other hand, it is not without significance that the ocular hypertension induced by the topical administration of glucocorticoids to normal subjects leaves the regulatory capacity intact although decreased in value (Langham 1967) .
Hereditary Aspect of Pressure Regulation It is well known that the incidence of open-angle glaucoma in the offspring of families with glaucoma is at least ten times in excess of the glaucoma incidence in the general population. If then we assume that the loss of pressure regulation leads to glaucoma it is important to know whether the glaucoma subject starts life with this abnormality. To find the answer, a comparative study was made of 50 young adolescents of families with no history of glaucoma and 50 adolescents who had at least one parent or grandparent with established open-angle glaucoma. The results summarized in a histogram are shown in Fig 2. The offspring of the glaucoma families showed a distribution of pressure regulatory capacity significantly lower than that of the offspring from normal families. Thus, there exists a strong possibility that glaucoma subjects may be identified many years before impairment of vision. This possibility is increased by my observations of glaucoma suspects who over a period of years developed field loss and who had shown loss of regulatory capacity several years previously.
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Adrenergic Mechanisms and Intraocular
I would like to consider in detail the role of these adrenergic mechanisms. I will confine my discussion to the role of the adrenergic mechanism in the human eye, and in particular to the response of the ocular tissues to norepinephrine, the transmitter substance of the sympathetic nervous system, which is an a-adrenergic agonist;
isoproterenol, a P-adrenergic agonist; and epinephrine, a catecholamine which shows both a-and P-adrenergic agonistic activity.
The ability of a-adrenergic mechanisms to decrease intraocular pressure and increase the outflow facility is seen in the response of normal eyes to norepinephrine applied topically (Table 2 ). In addition to showing vasomotor activity norepinephrine also acts on the myoepithelial cells of the iris to cause pupillary dilatation. This response is easy to quantitate and provides a good indication of the sensitivity of the a-adrenergic The responses of the human eye to norepinephrine are similar to those observed in conscious rabbits and lightly ancsthetized monkeys. In these species confirmation of the a-adrenergic mechanisms has been derived from observations that the responses to norepinephrine may be blocked by prior administration of the a-adrenergic antagonist, phenoxybenzamine (Langham 1965 , Kitazawa & Langham 1968 .
The presence of ,-adrenergic mechanisms in the human eye capable of effecting reduced intraocular pressure in a qualitatively different manner from norepinephrine has been demonstrated by isoproterenol applied topically. This catecholamine reduces intraocular pressure without either pupil dilatation or increased outflow facility (Table 3) . These responses are also identical to those observed in rabbits and monkeys and may be blocked by the P-adrenergic receptor antagonist propranolol (Langham 1965 , Kitazawa & Langham 1968 ).
Epinephrine, a catecholamine which has been widely used in the treatment of glaucoma is more complex in its action on animal and human eyes in that it is an agonist for both a-and ,-adrenergic receptors. Its ocular effect differs quantitatively from norepinephrine in that mydriasis is more difficult to elicit, and that it may induce pressure decrease without either pupil dilatation or increased outflow facility (Langham et al. 1971) . In this respect epinephrine in the concentrations available for therapy of glaucoma closely resembles the action of isoproterenol (Langham etal. 1971 ).
The ability of both a-and P-adrenergic mechanisms to decrease intraocular pressure both in normal animal and in human eyes raises a distinct possibility that the anatomical functional interrelationship is qualitatively similar in the different species. This viewpoint finds support in fluorescent histochemical and electron microscopic studies of the adrenergic innervation of 17-6+±10 16-1±1*2 16-0±0 9 12-8±0 9 16-3 ±0-8 14-9 ±0-9
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-0-02±0 01 50 ,tl of0 05 mol/I dl-isoproterenol was applied tcpically to the experimental eye at T = 0 hour. *measured by Goldmann applanation tonometer E measured by the Schiotz indentation tonographic procedure A difference in pairs of eyes of the 16 individual subjects the eye. In man and all animal species a dense adrenergic innervation of the iris, ciliary body and a less dense network to the intrascleral vessels has been found (Staflova 1969a , b, Ehinger 1966 . It would seem, therefore, that the role of adrenergic mechanisms in regulating intraocular pressure in animals is a good indication of a similar mechanism in normal man. Unfortunately, confirmation of this hypothesis has not yet been possible, for the necessary manometric and electrophysiological experiments can only be performed in animals. Nevertheless, let us accept the assumption that adrenergic control of intraocular pressure in man is similar to that demonstrable in animals and see how well this may help unravel the problem of glaucoma therapy.
The important question facing us several years ago was whether we could use our new understanding of the role of the sympathetic nervous system, the adrenergic receptors and catecholamines in regulating pressure in animal eyes to influence favourably the intraocular pressure and fluid circulation in the glaucomatous eye in ways better than are presently available to us. Several theoretical possibilities were considered, including the use of denervation supersensitivity induced either surgically or pharmacologically or, alternatively, potentiation of the effect of normal sympathetic nervous activity and exogenously administered catecholamines on the ocular tissues. I would like to consider our choice of adrenergic potentiation as this has become the principal basis of our new therapeutic approach to glaucoma.
The ability of certain antidepressants to potentiate the peripheral action of norepinephrine has been related to their ability to inhibit the uptake of norepinephrine into the adrenergic neurone (see Langham & Carmel 1968) . In this connexion it has become increasingly clear that neuronal uptake of the adrenergic transmitter norepinephrine is the principal mechanism for terminating the adrenergic response. To elucidate the potential application of this concept to influence favourably intraocular pressure, I chose the compound protriptyline (Fig 4) because it was known to be an active adrenergic potentiator and a powerful inhibitor of norepinephrine uptake into the adrenergic neurone (Malmfors 1965 ). In addition, its chemical stability and aqueous solubility made it suitable for topical administration on the eye. Recently, we have extended our studies to include an oxygen bridged analogue of protriptyline (Fig 4) which appears to be less irritating than protriptyline to the cornea and to have more specific adrenergic properties (Langham & Diggs 1971) .
The ability of protriptyline to potentiate the ocular response both to norepinephrine released endogenously or norepinephrine applied topically in animals and man has been documented (Langham & Carmel 1968 , Kitazawa & Langham 1968 , 1971a , b, Langham et al. 1971 . Typical results on normal subjects are shown in Figs 5 and 6. The adrenergic potentiation of norepinephrine applied topically has been found to correspond to a shift of the dose-response curve by approximately 15 times, which indicates a greater than 90% inhibition of norepinephrine uptake (Langham & Diggs 1971) . It is of particular significance that the duration of the pressure response to norepinephrine may be increased to more than twenty-four hours (Fig 6) .
In an extension of the studies on norepinephrine and protriptyline, Kitazawa & Langham (1968) compared the potentiating activity of protriptyline on the ocular response to the a-and ,-adrenergic agonistsnorepinephrine, epinephrine and isoproterenol in rhesus monkeys. They found the potentiation of the epinephrine response to be much less than for norepinephrine and absent for isoproterenol. Similar conclusions were later found in analogous studies on normal subjects (Kitazawa & Langham 1971a , b, Langham et al. 1971 . We therefore arrive at the concept that open-angle glaucoma is a neurovascular disease in which there is a failure of the adrenergic mechanisms to regulate and stabilize the intraocular pressure. Two questions, one theoretical and one clinical, remain to be answered: (l) Do a-and P-adrenergic mechanisms act to reduce intraocular pressure in the glaucomatous eye and does neuronal uptake of norepinephrine limit the response in the glaucomatous eye? (2) What qualitative and quantitative differences are we to expect in the responses of glaucomatous eyes to the catecholamines and adrenergic potentiators ? Before presenting experimental observations relating to these questions, it is important to emphasize that the marked instability of intraocular pressure in the glaucomatous subject means that strictly controlled experimental procedures must be adhered to in order to interpret correctly whether an ocular response is due either to the drug or to a spontaneous variability of intraocular pressure. The spontaneous variation in intraocular pressure is minimized when the glaucoma patient is kept in bed and it is under these conditions that the most definitive results may be obtained. This problem of drug evaluation in glaucoma is compounded by the fact that whereas no contralateral effects are seen in the adrenergic treatment of normal eyes, it has been found that reduction of an elevated intraocular pressure in glaucomatous eyes can induce a consensual pressure decrement (Kitazawa & Langham, unpublished) . Fortunately, the consensual response is normally small compared with the direct effect of the drug on the treated eye, and consequently, the untreated eye may be used as a reference.
The effectiveness of a-adrenergic agonists, e.g. norepinephrine, to decrease intraocular pressure in the glaucomatous patient has been established (Kitazawa & Langham 1971b ). Significant reduction in intraocular pressure associated with increased outflow facility was sustained over the seven-day period of treatment. Withdrawal of the norepinephrine led to a reversal of the response.
It is of clinical interest that the pressure and outflow facility responses to norepinephrine closely simulate, qualitatively and quantitatively, those observed by Linner (1958) in his wellcontrolled study of the response of the glaucomatous eye to pilocarpine.
In similar stldies isoproterenol, the ,3-adrenergic agonist, was found to decrease intraocular pressure without either pupil dilatation or increased outflow facility in glaucomatous eyes (Kitazawa & Langham 1971b) . These results agree with those recently reported by Ross & Drance (personal communication).
The old and well-established observations that epinephrine with its a-and P-adrenergic activity may reduce intraocular pressure, increase outflow facility and decrease aqueous humour formation in early and advanced cases of open-angle glaucoma add further weight to the conclusion that in the glaucomatous eye the responses to a-and P-adrenergic agonists are qualitatively similar to those of normal eyes.
We now turn to the action of neuronal uptake in limiting the pressure response in the glaucomatous eye to a-adrenergic agonists and in particular to norepinephrine. This has been investigated by comparing the response of eyes of individual glaucomatous patients to norepinephrine alone or to a combination of norepinephrine and an adrenergic potentiator. The results showed significant potentiation both in terms of pupil dilatation and in increased time of pressure response (Kitazawa & Langham 1971b ). It is on the basis of these results confirming the qualitative similarity of the adrenergic response in normal and glaucomatous eyes that we may clarify the clinical approach to the individual patient. The important question will arise each time a patient is seen whether the quantitative responses to drug therapy will reduce the pressure sufficiently to slow or stop progression of the disease. In keeping with all forms of medical and surgical treatment of glaucoma, it must be anticipated that the success of adrenergic therapy will be greatest when the glaucoma is diagnosed early. In this respect adrenergic therapy would appear to have significant theoretical and practical advantages over miotic therapy.
Pilocarpine therapy has to contend with two unfortunate side-effects. First, the spasm of accommodation which may impair vision for one to two hours following topical administration of the drug; second, the induction of extreme miosis and an immobile pupil which curtails night vision. The adrenergic potentiator alone or in combination with norepinephrine has neither of these disadvantages. The effect on accommodation is generally negligible and the pupil remains mobile and, of course, is not constricted.
A further potential of the adrenergic therapy over pilocarpine is seen in its ability to influence intraocular pressure and the regulatory capacity in normal eyes (Langham & Carmel 1968) . These positive responses are in marked contrast to the inability of pilocarpine to induce a sustained decrease of pressure in normal eyes even though it causes marked miosis (Willetts 1968) .
In a patient with advanced glaucoma the prospects of halting progressive loss of vision may best be evaluated by assessing the patient's regulatory capacity (Langham & Maumenee 1964) . If the regulatory capacity is unresponsive to therapy, even though the intraocular pressure appears to be in the normal range, glaucoma surgery is probably the only recourse. I have said the pressure 'appears to be low' because I feel that if the regulatory capacity is not functioning the pressures will inevitably fluctuate and rise. If, however, the regulatory capacity is responsive to adrenergic therapy and the pressure remains normal, the prognosis is good. Of course, nothing can be done to reverse structural damage to retinal tissue if it has already occurred.
In conclusion, I will refer to the anatomical aspects of the vascular control of intraocular pressure which we are hoping to elucidate.
Norepinephrine, the a-adrenergic agonist, generally acts by constricting blood vessels, whereas isoproterenol is a vasodilator. Thus, it is necessary to explain why vasoconstriction increases outflow facility and vasodilatation decreases aqueous humour formation. The problem appears paradoxical at first sight, but I would like to suggest that the explanation will be found on the basis that the rate of bloodflow to the ciliary processes determines the rate of aqueous humour formation and that aqueous humour and blood compete for the same channels.
Experimental evidence that aqueous humour formation is proportionate to bloodflow to the ciliary processes has been found by Langham & Rosenthal (1966) in studies in which decreased bloodflow was induced by electrical stimulation of the preganglionic cervical sympathetic nerve. In human subjects a similar correlation most probably explains the significant reduction of aqueous humour formation that occurs over the age of 60 years (Langham 1967) . In the outflow system the competition of blood and aqueous humour for the same exit veins finds support in the many studies on aqueous veins and in the detailed studies of Ashton (1951 Ashton ( , 1952 .
Under these conditions it may be hypothesized that vasoconstriction in the blood vessels leading to the intrascleral venous plexus would decrease the vascular filling of the system and result in increased facility of outflow of the aqueous humour. Similarly, the action of isoproterenol in decreasing the rate of aqueous humour formation would be visualized in terms of drawing off blood from the ciliary processes by vasodilatation.
Evidence consistent with a shunting of blood from the ciliary processes has been put forward recently by Cole & Rumble (1970) . The anatomical observations of Kiss (1943) on the anterior ciliary plexus are of special interest in this connexion. Kiss showed by perfusion techniques the presence of relatively large veins connecting directly with the episcleral venous system. Adrenergic innervation of vessels in this area have been described (Ehinger 1966) and it is this system which appears to provide the means of modifying bloodflow both to the ciliary processes and to the intraand epi-scleral plexuses. The general nature of this neurovascular concept of regulation of intraocular pressure and aqueous humour dynamics has recently found strong support in the exciting and extensive theoretical analysis of Hart (1970) .
Concepts are the essential stepping stones leading to new knowledge. The value of the concept rapidly wanes when it is no longer able to explain and unify experimental observations. It was the inadequacy of current concepts of aqueous humour dynamics to explain regulation of intraocular pressure (see Langham 1958 ) that led me to seek alternative experimental approaches to the problem. The resulting concept which has been presented in this paper will doubtless undergo modification, but it has already served well in providing the scientific rationale for the development of a new drug therapy for glaucoma and its prevention. Now is the opportunity for is wider consideration and application of this knowledge.
Finally, I would like to pay tribute to the enthusiastic research collaborators working in the specialties of physiology, electron microscopy, pharmacology, biophysics and the clinical sciences who have made this research endeavour possible.
